Comparison of Anti-SARS-CoV-2 IgG Antibody Responses Generated by the Administration of Ad26.COV2.S, AZD1222, BNT162b2, or CoronaVac: Longitudinal Prospective Cohort Study in the Colombian Population, 2021/2022

Abstract

To mitigate the coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), vaccines have been rapidly developed and introduced in many countries. In Colombia, the population was vaccinated with four vaccines. Therefore, this research aimed to determine the ability of the vaccines introduced in the National Vaccination Plan to prevent SARS-CoV-2 infection and induce seroconversion and sought to investigate the longevity of antibodies in the blood. We conducted a prospective, nonprobabilistic, consecutive cross-sectional cohort study in a population with access to vaccination with CoronaVac, Ad26.COV2.S, AZD1222, and BNT162b2 from March 2021 to March 2022. The study included 1327 vaccinated people. A plurality of participants were vaccinated with BNT162b2 (36.1%; n = 480), followed by Ad26.COV2.S (26.9%; n = 358), CoronaVac (24%; n = 331), and AZD1222 (11.9%; n = 158). The crude seroprevalence on day zero varied between 18.1% and 57.8%. Participants who received BNT162b2 had a lower risk of SARS-CoV-2 infection than those who received the other vaccines. Participants who were immunized with BNT162b2 and AZD1222 had a higher probability of losing reactivity on day 210 after receiving the vaccine.

Seroprevalence of SARS-CoV-2 anti-spike IgG antibody among COVID-19 vaccinated individuals residing in Surabaya, East Java, Indonesia

“…Older individuals, mostly more than 60 years old, experienced higher seronegativity after taking two doses of almost any type of COVID-19 vaccines, including CoronaVac, AstraZeneca, and Moderna ( Fonseca et al, 2022 ; Chiarella et al, 2022 ; Malagón-Rojas et al, 2022 ). The seronegativity might happen due to immunescence, which may decrease the immune response due to the reduction of T-cell proliferation, naïve T-cell population, cytokine production, and antigen recognition ( Fulop et al, 2009 ).…”

Neutralizing Antibody Responses Elicited by Inactivated Whole Virus and Genetic Vaccines against Dominant SARS-CoV-2 Variants during the Four Epidemic Peaks of COVID-19 in Colombia

“…This was a non-probabilistic, consecutive cross-sectional study of four Colombian cohorts included in the National Vaccination Plan during the prioritization phase [19]. The first three cohorts received a vaccination schedule of two doses at four-week intervals of BNT162b2 (Pfizer), ChAdOx1 (AstraZeneca), or CoronaVac (Sinovac).…”